Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders.
Bouwman
Femke H
FH
van der Flier
Wiesje M
WM
Schoonenboom
Niki S M
NS
van Elk
Evert J
EJ
Kok
Astrid
A
Scheltens
Philip
P
Blankenstein
Marinus A
MA
D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D003072:Cognition Disorders / Q000134:cerebrospinal fluid* / Q000175:diagnosis; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008137:Longitudinal Studies; D009422:Nervous System Diseases / Q000134:cerebrospinal fluid* / Q000175:diagnosis; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D013048:Specimen Handling; D013997:Time Factors
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42)